SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
BeiGene, Ltd. (BGNE) trades at a trailing P/E of 5.6, forward P/E of 53.6. Trailing earnings yield is 17.79%, forward earnings yield 1.86%. PEG 0.90 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (94/100, Pass) — P/E is below market average (5.6); PEG ≤ 1.0 — Peter Lynch undervalued (0.90); analyst target implies upside (+39.7%); earnings yield beats bond yields (17.79%).
- PEG Ratio 0.90 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 17.79% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
- Analyst consensus target $258.00 (+39.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 73/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
94/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BGNE
Valuation Multiples
P/E (TTM)5.6
Forward P/E53.6
PEG Ratio0.90
Forward PEG0.90
P/B Ratio0.00
P/S Ratio3.92
EV/EBITDA0.0
Per Share Data
EPS (TTM)$32.89
Forward EPS (Est.)$3.44
Book Value / Share$0.00
Revenue / Share$47.10
FCF / Share$0.00
Yields & Fair Value
Earnings Yield17.79%
Forward Earnings Yield1.86%
Dividend Yield0.00%
Analyst Target$258.00 (+39.7%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-3.90 |
$1.07M |
$-119.22M |
-11141.8% |
| 2017 |
$-2.21 |
$238.39M |
$-93.11M |
-39.1% |
| 2018 |
$-12.09 |
$198.22M |
$-673.77M |
-339.9% |
| 2019 |
$-15.86 |
$428.21M |
$-950.58M |
-222% |
| 2020 |
$-19.11 |
$308.87M |
$-1.6B |
-518.2% |
| 2021 |
$-15.21 |
$1.18B |
$-1.41B |
-120.2% |
| 2022 |
$-19.37 |
$1.42B |
$-2B |
-141.5% |
| 2023 |
$-8.45 |
$2.46B |
$-881.71M |
-35.9% |
| 2024 |
$-6.11 |
$3.81B |
$-644.79M |
-16.9% |
| 2025 |
$32.89 |
$5.34B |
$286.93M |
5.4% |
